AstraZeneca's lung cancer drug approved in China: AstraZeneca said that its Tagrisso medicine has been approved in China for the treatment of early lung cancer. The UK-based pharmaceutical giant said Tagrisso is the first such drug to have received approval in China, as well as the only one to have shown efficacy against the disease in a global trial.
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
AstraZeneca’s Tagrisso was approved in China for lung cancer treatment
AstraZeneca's lung cancer drug approved in China
The FTSE 100 company added that the approval is based on the positive results coming from the Adaura Phase 3 trial, where Tagrisso was proven to reduce the risk of disease recurrence or death by 80%.
